Pfizer ends development deal with Pain Therapeutics
October 27, 2014 at 14:25 PM EDT
Pfizer
Inc. (NYSE: PFE) ended its development agreement with Pain Therapeutics
Inc. (Nasdaq: PTIE) for the pain treatment Remoxy. Shares of Pfizer
eased a penny to $29.10 while Pain Therapeutics stock plunged $2.11 to
$2.04.
